journal
MENU ▼
Read by QxMD icon Read
search

Cancer Metastasis Reviews

journal
https://www.readbyqxmd.com/read/29327093/mir-181-family-specific-behavior-in-different-cancers-a-meta-analysis-view
#1
Cecilia Pop-Bica, Sebastian Pintea, Roxana Cojocneanu-Petric, Giannino Del Sal, Silvano Piazza, Zhao-Hui Wu, Alvaro J Alencar, Izidore S Lossos, Ioana Berindan-Neagoe, George A Calin
The involvement of microRNAs in malignant transformation and cancer progression was previously grounded. The observations made by multiple published studies led to the conclusion that some of these small sequences could be eventually used as biomarkers for diagnosis/prognosis. This meta-analysis investigated whether microRNA-181 family members could predict the outcome of patients carrying different types of cancer. We searched the PubMed and Embase databases for studies evaluating the expression levels of miR-181a/b/c/d in patients with cancer, selecting the publications that assessed the relation between low and high levels of one of these four microRNAs and patients' outcome...
January 11, 2018: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29322354/mutations-of-key-driver-genes-in-colorectal-cancer-progression-and-metastasis
#2
REVIEW
Dongdong Huang, Wenjie Sun, Yuwei Zhou, Peiwei Li, Fang Chen, Hanwen Chen, Dajing Xia, Enping Xu, Maode Lai, Yihua Wu, Honghe Zhang
The association between mutations of key driver genes and colorectal cancer (CRC) metastasis has been investigated by many studies. However, the results of these studies have been contradictory. Here, we perform a comprehensive analysis to screen key driver genes from the TCGA database and validate the roles of these mutations in CRC metastasis. Using bioinformatics analysis, we identified six key driver genes, namely APC, KRAS, BRAF, PIK3CA, SMAD4 and p53. Through a systematic search, 120 articles published by November 30, 2017, were included, which all showed roles for these gene mutations in CRC metastasis...
January 10, 2018: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29318445/functions-of-the-apc-tumor-suppressor-protein-dependent-and-independent-of-canonical-wnt-signaling-implications-for-therapeutic-targeting
#3
REVIEW
William Hankey, Wendy L Frankel, Joanna Groden
The acquisition of biallelic mutations in the APC gene is a rate-limiting step in the development of most colorectal cancers and occurs in the earliest lesions. APC encodes a 312-kDa protein that localizes to multiple subcellular compartments and performs diverse functions. APC participates in a cytoplasmic complex that promotes the destruction of the transcriptional licensing factor β-catenin; APC mutations that abolish this function trigger constitutive activation of the canonical WNT signaling pathway, a characteristic found in almost all colorectal cancers...
January 9, 2018: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29285656/preface
#4
EDITORIAL
George A Calin, Katrien Van Roosbroeck
No abstract text is available yet for this article.
December 29, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29282605/mir-155-in-cancer-drug-resistance-and-as-target-for-mirna-based-therapeutics
#5
REVIEW
Recep Bayraktar, Katrien Van Roosbroeck
Small non-coding microRNAs (miRNAs) are instrumental in physiological processes, such as proliferation, cell cycle, apoptosis, and differentiation, processes which are often disrupted in diseases like cancer. miR-155 is one of the best conserved and multifunctional miRNAs, which is mainly characterized by overexpression in multiple diseases including malignant tumors. Altered expression of miR-155 is found to be associated with various physiological and pathological processes, including hematopoietic lineage differentiation, immune response, inflammation, and tumorigenesis...
December 27, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29270700/diagnostic-and-therapeutic-applications-of-mirna-based-strategies-to-cancer-immunotherapy
#6
Gabriele Romano, Lawrence N Kwong
Cancer immunotherapy has shown impressive clinical results in the last decade, improving both solid and hematologic cancer patients' overall survival. Nevertheless, most of the molecular aspects underlying the response to this approach are still under investigation. miRNAs in particular have been described as regulators of a plethora of different immunologic processes and thus have the potential to be key in the future developments of immunotherapy. In this review, we summarize and discuss the emerging role of miRNAs in the diagnosis and therapeutics of the four principal cancer immunotherapy approaches: immune checkpoint blockade, adoptive cell therapy, cancer vaccines, and cytokine therapy...
December 21, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29260351/correction-to-cancer-driver-g-protein-coupled-receptor-gpcr-induced-%C3%AE-catenin-nuclear-localization-the-transcriptional-junction
#7
Jeetendra Kumar Nag, Tatyana Rudina, Myriam Maoz, Sorina Grisaru-Granovsky, Beatrice Uziely, Rachel Bar-Shavit
The original version of this article unfortunately contained a mistake. The family name of Beatrice Uziely was mistakenly spelled as Uzieky. The correct name is now presented above.
December 20, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29247341/from-biomarkers-to-therapeutic-targets-the-promises-and-perils-of-long-non-coding-rnas-in-cancer
#8
Tony Gutschner, Georg Richtig, Monika Haemmerle, Martin Pichler
Biomarker-driven personalized cancer therapy is a field of growing interest, and several molecular tests have been developed to detect biomarkers that predict, e.g., response of cancers to particular therapies. Identification of these molecules and understanding their molecular mechanisms is important for cancer prognosis and the development of therapeutics for late stage diseases. In the past, significant efforts have been placed on the discovery of protein or DNA-based biomarkers while only recently the class of long non-coding RNA (lncRNA) has emerged as a new category of biomarker...
December 15, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29243000/rna-interference-based-therapy-and-its-delivery-systems
#9
Xiuhui Chen, Lingegowda S Mangala, Cristian Rodriguez-Aguayo, Xianchao Kong, Gabriel Lopez-Berestein, Anil K Sood
RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi...
December 14, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29234933/micrornas-and-metastasis-small-rnas-play-big-roles
#10
Jongchan Kim, Fan Yao, Zhenna Xiao, Yutong Sun, Li Ma
MicroRNAs (miRNAs) are small non-coding RNAs regulating post-transcriptional gene expression. They play important roles in many biological processes under physiological or pathological conditions, including development, metabolism, tumorigenesis, metastasis, and immune response. Over the past 15 years, significant insights have been gained into the roles of miRNAs in cancer. Depending on the cancer type, miRNAs can act as oncogenes, tumor suppressors, or metastasis regulators. In this review, we focus on the role of miRNAs as components of molecular networks regulating metastasis...
December 12, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29230620/long-non-coding-rnas-in-metastasis
#11
Qihong Huang, Jinchun Yan, Reuven Agami
Long non-coding RNA (lncRNA) genes have recently been discovered as key regulators of developmental, physiological, and pathological processes in humans. Recent studies indicate that lncRNAs regulate every step of gene expression, and their aberrant expression can be found in the majority of cancer types. Particularly, lncRNAs were found to function in tumor development and metastasis, which is the major cause of cancer-related death. Thus, exploring key roles of lncRNAs in metastasis is predicted to enhance our knowledge of metastasis, and uncover novel therapeutic targets and biomarkers of this process...
December 11, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29222765/cancer-driver-g-protein-coupled-receptor-gpcr-induced-%C3%AE-catenin-nuclear-localization-the-transcriptional-junction
#12
REVIEW
Jeetendra Kumar Nag, Tatyana Rudina, Myriam Maoz, Sorina Grisaru-Granovsky, Beatrice Uzieky, Rachel Bar-Shavit
G protein-coupled receptors (GPCRs) comprise the main signal-transmitting components in the cell membrane. Over the past several years, biochemical and structural analyses have immensely enhanced our knowledge of GPCR involvement in health and disease states. The present review focuses on GPCRs that are cancer drivers, involved in tumor growth and development. Our aim is to highlight the involvement of stabilized β-catenin molecular machinery with a specific array of GPCRs. We discuss recent advances in understanding the molecular path leading to β-catenin nuclear localization and transcriptional activity and their implications for future cancer therapy research...
December 8, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29196868/the-proteasome-and-proteasome-inhibitors-in-multiple-myeloma
#13
Sara Gandolfi, Jacob P Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C Anderson, Paul G Richardson
Proteasome inhibitors are one of the most important classes of agents to have emerged for the treatment of multiple myeloma in the past two decades, and now form one of the backbones of treatment. Three agents in this class have been approved by the United States Food and Drug Administration-the first-in-class compound bortezomib, the second-generation agent carfilzomib, and the first oral proteasome inhibitor, ixazomib. The success of this class of agents is due to the exquisite sensitivity of myeloma cells to the inhibition of the 26S proteasome, which plays a critical role in the pathogenesis and proliferation of the disease...
December 2, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29134486/proteasome-associated-deubiquitinases-and-cancer
#14
Arjan Mofers, Paola Pellegrini, Stig Linder, Pádraig D'Arcy
Maintenance of protein homeostasis is a crucial process for the normal functioning of the cell. The regulated degradation of proteins is primarily facilitated by the ubiquitin proteasome system (UPS), a system of selective tagging of proteins with ubiquitin followed by proteasome-mediated proteolysis. The UPS is highly dynamic consisting of both ubiquitination and deubiquitination steps that modulate protein stabilization and degradation. Deregulation of protein stability is a common feature in the development and progression of numerous cancer types...
November 14, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29080080/ubiquitin-carboxyl-terminal-hydrolases-involvement-in-cancer-progression-and-clinical-implications
#15
Ying Fang, Xizhong Shen
Protein ubiquitination and deubiquitination participate in a number of biological processes, including cell growth, differentiation, transcriptional regulation, and oncogenesis. Ubiquitin C-terminal hydrolases (UCHs), a subfamily of deubiquitinating enzymes (DUBs), includes four members: UCH-L1/PGP9.5 (protein gene product 9.5), UCH-L3, UCHL5/UCH37, and BRCA1-associated protein-1 (BAP1). Recently, more attention has been paid to the relationship between the UCH family and malignancies, which play different roles in the progression of different tumors...
October 27, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29071527/-immuno-proteasomes-as-therapeutic-target-in-acute-leukemia
#16
Jacqueline Cloos, Margot Sf Roeten, Niels E Franke, Johan van Meerloo, Sonja Zweegman, Gertjan Jl Kaspers, Gerrit Jansen
The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress...
October 25, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29071526/the-ubiquitin-proteasome-pathway-in-adult-and-pediatric-brain-tumors-biological-insights-and-therapeutic-opportunities
#17
Wafik Zaky, Christa Manton, Claudia P Miller, Soumen Khatua, Vidya Gopalakrishnan, Joya Chandra
Nearly 20 years ago, the concept of targeting the proteasome for cancer therapy began gaining momentum. This concept was driven by increased understanding of the biology/structure and function of the 26S proteasome, insight into the role of the proteasome in transformed cells, and the synthesis of pharmacological inhibitors with clinically favorable features. Subsequent in vitro, in vivo, and clinical testing culminated in the FDA approval of three proteasome inhibitors-bortezomib, carfilzomib, and ixazomib -for specific hematological malignancies...
October 25, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29218510/biography-q-ping-dou
#18
(no author information available yet)
No abstract text is available yet for this article.
December 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29047025/targeting-the-ubiquitin-proteasome-system-for-cancer-treatment-discovering-novel-inhibitors-from-nature-and-drug-repurposing
#19
Claire L Soave, Tracey Guerin, Jinbao Liu, Q Ping Dou
In the past 15 years, the proteasome has been validated as an anti-cancer drug target and 20S proteasome inhibitors (such as bortezomib and carfilzomib) have been approved by the FDA for the treatment of multiple myeloma and some other liquid tumors. However, there are shortcomings of clinical proteasome inhibitors, including severe toxicity, drug resistance, and no effect in solid tumors. At the same time, extensive research has been conducted in the areas of natural compounds and old drug repositioning towards the goal of discovering effective, economical, low toxicity proteasome-inhibitory anti-cancer drugs...
December 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29052093/emerging-small-molecule-approaches-to-enhance-the-antimyeloma-benefit-of-proteasome-inhibitors
#20
James J Driscoll, Magen Brailey
Multiple myeloma (MM) is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 118,000 patients in the USA afflicted with this disease. Treatment of MM has dramatically improved in the past decade with the introduction of new drugs into therapeutic strategies in both the frontline and relapse settings that has led to a significant improvement in the median overall survival (OS). These drugs have been incorporated into clinical guidelines and transformed the treatment approach to MM...
October 19, 2017: Cancer Metastasis Reviews
journal
journal
29260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"